

Certification of Substances Department

Certificate of suitability
No. R1-CEP 2011-004-Rev 01

- 1 *Name of the substance:*
2 **TAMSULOSIN HYDROCHLORIDE**
- 3 *Name of holder:*
4 **SCINOPHARM TAIWAN, LTD.**
5 No. 1, Nan-Ke 8th Road
6 Taiwan-74144 Shan-Hua, Tainan
- 7 *Site(s) of production:*
8 **SEE ANNEX 1**

9
10 **Notice**
11 **NOT FOR REGISTRATION PURPOSES**
12 **For filing purposes please contact ScinoPharm Taiwan**
13 **to obtain a complete "controlled copy" of this CEP.**
14
15 **ScinoPharm Taiwan- Regulatory Technical Services**
16 **(SPT.RTS@scinopharm.com.tw)**
17

18 the test for loss on drying described in the monograph with a limit of not more than 0.5%.

19 A risk management summary for elemental impurities has been provided. (Annex 2)

20 – Test for elemental impurities by ICP-MS (Annex 3)

21 Palladium not more than 10 ppm


22 Nickel not more than 20 ppm

23 The re-test period of the substance is 5 years if stored in double polyethylene bags, placed in
24 either a polyethylene bottle or a polyethylene drum.

25 The holder of the certificate has declared the absence of use of material of human or animal
26 origin in the manufacture of the substance.

27 The submitted dossier must be updated after any significant change that may alter the quality,
28 safety or efficacy of the substance.

- 29 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice
30 and in accordance with the dossier submitted.
- 31 Failure to comply with these provisions will render this certificate void.
- 32 This certificate is renewed from **27 June 2018** according to the provisions of Resolution AP-CSP
33 (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent amendment,
34 and the related guidelines.
- 35 This certificate has three annexes, the first and the second of 1 page each and the third of
36 3 pages.
- 37 This certificate has:
38 lines.


On behalf of the
Director of EDQM



Strasbourg, 22 January 2020

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

Notice
NOT FOR REGISTRATION PURPOSES
For filing purposes please contact ScinoPharm Taiwan
to obtain a complete "controlled copy" of this CEP.

ScinoPharm Taiwan- Regulatory Technical Services
(SPT.RTS@scinopharm.com.tw)

to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*: